Evidence map›Paper›PMID 26187043›Full record

ArticleBMC cancer2015

TKTL1 expression in human malign and benign cell lines.

Ulrike Kämmerer, Olivier Gires, Nadja Pfetzer, Armin Wiegering, Rainer Johannes Klement, Christoph Otto

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ulrike KämmererDepartment of Obstetrics and Gynaecology, University of Würzburg Hospital, Josef-Schneider-Str. 4, D-97080, Würzburg, Germany. frak057@mail.uni-wuerzburg.de.
Olivier GiresDepartment of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University, Marchioninistr. 15, D-81377, Munich, Germany. Olivier.gires@med.uni-muenchen.de.
Nadja PfetzerDepartment of Obstetrics and Gynaecology, University of Würzburg Hospital, Josef-Schneider-Str. 4, D-97080, Würzburg, Germany. N.Pfetzer@beatson.gla.ac.uk.
Armin WiegeringDepartment of General, Visceral, Vascular and Paediatric Surgery, University Hospital of Würzburg, Oberdürrbacher Str. 6, D-97080, Würzburg, Germany. Wiegering_A@ukw.de.
Rainer Johannes KlementDepartment of Radiotherapy and Radiation Oncology, Leopoldina Hospital Schweinfurt, Gustav-Adolf-Straße 8, D-97422, Schweinfurt, Germany. rainer_klement@gmx.de.
Christoph OttoExperimental Surgery, Experimental Transplantation Immunology, Department of General, Visceral, Vascular and Paediatric Surgery, University Hospital of Würzburg, Oberdürrbacher Str. 6, D-97080, Würzburg, Germany. Otto_c@ukw.de.
Universitätsklinikum Würzburg · DELeopoldina Krankenhaus Schweinfurt · DELudwig-Maximilians-Universität München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOverexpression of transketolase-like 1 protein TKTL1 in cancer cells has been reported to correlate with enhanced glycolysis and lactic acid production. Furthermore, enhanced TKTL1 expression was put into context with resistance to chemotherapy and ionizing radiation. Here, a panel of human malign and benign cells, which cover a broad range of chemotherapy and radiation resistance as well as reliance on glucose metabolism, was analyzed in vitro for TKTL1 expression.

methods17 malign and three benign cell lines were characterized according to their expression of TKTL1 on the protein level with three commercially available anti-TKTL1 antibodies utilizing immunohistochemistry and Western blot, as well as on mRNA level with three published primer pairs for RT-qPCR. Furthermore, sensitivities to paclitaxel, cisplatin and ionizing radiation were assessed in cell survival assays. Glucose consumption and lactate production were quantified as surrogates for the "Warburg effect".

resultsConsiderable amounts of tktl1 mRNA and TKTL1 protein were detected only upon stable transfection of the human embryonic kidney cell line HEK293 with an expression plasmid for human TKTL1. Beyond that, weak expression of endogenous tktl1 mRNA was measured in the cell lines JAR and U251. Western blot analysis of JAR and U251 cells did not detect TKTL1 at the expected size of 65 kDa with all three antibodies specific for TKTL1 protein and immunohistochemical staining was observed with antibody JFC12T10 only. All other cell lines tested here revealed expression of tktl1 mRNA below detection limits and were negative for TKTL1 protein. However, in all cell lines including TKTL1-negative HEK293-control cells, antibody JFC12T10 detected multiple proteins with different molecular weights. Importantly, JAR and U251 did neither demonstrate an outstanding production of lactic acid nor increased resistance against chemotherapeutics or to ionizing radiation, respectively.

conclusionUsing RT-qPCR and three different antibodies we observed only exceptional occurrence of TKTL1 in a panel of malignant human cell lines in vitro. The presence of TKTL1 was unrelated to either the rate of glucose consumption/lactic acid production or resistance against chemo- and radiotherapy.

Indexed as

Antineoplastic AgentsCell LineCell SurvivalCisplatinDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticGlucoseHCT116 CellsHEK293 CellsHeLa CellsHumansHuman Umbilical Vein Endothelial CellsLactic AcidMCF-7 CellsPaclitaxelRadiation ToleranceAntineoplastic AgentsCisplatinGlucoseLactic AcidPaclitaxelTKTL1 protein, humanTransketolase

Identifiers

PMID26187043
PMCPMC4506423
OpenAlexW1594184184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.